Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

CNTO1959PSO3018: A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Guselkumab for the Treatment of Participants With Skin of Color Who Have Moderate-to-Severe Plaque Psoriasis and/or Moderate

NCT05272150 is registered in ClinicalTrials.gov with Janssen Research & Development, LLC as lead sponsor.

NCT NCT05272150
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05272150 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
CNTO1959PSO3018: A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Guselkumab for the Treatment of Participants With Skin of Color Who Have Moderate-to-Severe Plaque Psoriasis and/or Moderate
Lead sponsor
Janssen Research & Development, LLC
Phase
Phase 3
Overall status
Completed
Start date
July 13, 2022
Completion date
May 30, 2025
Enrollment
211 (actual)
Sites
94

Conditions

As the registry lists them; a condition with its own page is linked.

plaque psoriasis, scalp psoriasis